Study S002592

A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naïve Patients With T2DM Inadequately Controlled on OAD Treatment in Turkey

ClinicalTrials.gov record

Registration

Registration: NCT02954692
Acronym: EASE
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 112
Start: 2016-11-30
Primary completion: 2017-12-22
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:INSULIN GLARGINE (U300); DRUG:metformin; DRUG:sulfonylurea; DRUG:meglitinides; DRUG:thiazolidinediones; DRUG:alpha-glucosidase inhibitors; DRUG:GLP1 Receptor Agonist; DRUG:Dipeptidyl peptidase-IV (DPP-IV) inhibitors; DRUG:Sodium-glucose transport-2 (SGLT-2) inhibitors
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1183-8755

Registered primary outcomes

Mean change from baseline in HbA1c [Baseline, Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.